Flublok® Quadrivalent Influenza Virus Vaccine — Competitive Intelligence Brief

Flublok® Quadrivalent Influenza Virus Vaccine (Flublok® Quadrivalent Influenza Virus Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Influenza vaccine. Area: Immunology / Infectious Disease.

phase 3 Influenza vaccine Influenza hemagglutinin (HA) antigen Immunology / Infectious Disease Biologic

Target snapshot

Flublok® Quadrivalent Influenza Virus Vaccine (Flublok® Quadrivalent Influenza Virus Vaccine) — Protein Sciences Corporation. Flublok stimulates the immune system to produce antibodies against four strains of influenza virus by presenting recombinant hemagglutinin antigens.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Flublok® Quadrivalent Influenza Virus Vaccine TARGET	Flublok® Quadrivalent Influenza Virus Vaccine	Protein Sciences Corporation	phase 3	Influenza vaccine	Influenza hemagglutinin (HA) antigen
Anti-H1N1v Vaccine	Anti-H1N1v Vaccine	Institut National de la Santé Et de la Recherche Médicale, France	marketed	Inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
CSL Influenza Vaccine	CSL Influenza Vaccine	Seqirus	marketed	inactivated influenza vaccine
H5N1 vaccine (Arepanrix)	H5N1 vaccine (Arepanrix)	Canadian Immunization Research Network	marketed	inactivated split-virion influenza vaccine with adjuvant
Hualan TIV	Hualan TIV	Sanofi	marketed	Inactivated influenza vaccine
Influenza Fluzone vaccine	Influenza Fluzone vaccine	La Jolla Institute for Immunology	marketed	inactivated influenza vaccine
CSL Limited Influenza Virus Vaccine	CSL Limited Influenza Virus Vaccine	Seqirus	marketed	inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Influenza vaccine class)

1. GlaxoSmithKline · 8 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
3. Seqirus · 2 drugs in this class
4. MedImmune LLC · 1 drug in this class
5. AstraZeneca · 1 drug in this class
6. Novartis · 1 drug in this class
7. Protein Sciences Corporation · 1 drug in this class
8. ModernaTX, Inc. · 1 drug in this class
9. Institute of Vaccines and Medical Biologicals, Vietnam · 1 drug in this class
10. Janssen Vaccines & Prevention B.V. · 1 drug in this class